Immune Checkpoint Inhibitors
Cardiotoxicity of immune checkpoint inhibitors
... cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific ...with immune checkpoint blockers (ie, monoclonal ...
12
Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
... Background: Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as ...
10
Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
... different immune checkpoint inhibitors, the addition of immune checkpoint inhibitors after resection or during locoregional therapy, immune checkpoint ...
10
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
... to checkpoint blockade is simply a reflection of the pres- ence of health-associated bacteria that are of usual higher quantities in healthier individuals with more robust and functional immune systems or ...
14
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
... assays, immune-related toxicity, and treatment duration are ...to immune checkpoint inhibitors, other immunotherapy tar- geting cytokines, tumor-directed antibodies, antibody-drug conjugates, ...
13
Immune checkpoint inhibitors in the treatment of virus-associated cancers
... The immune system is the “ guard ” of the human body, resisting the invasion of foreign substances such as ...of immune checkpoint inhibitors (ICIs) in recent years has opened a new door to ...
10
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
... the immune system responds effectively to both external and internal threats without damaging healthy ...host’s immune response ceases, which prevents tissue damage or chronic ...how ...
20
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
... chemotherapy. Immune checkpoint inhibitors with their favorable toxicity profiles and notable antitumor activity have ushered in a new era in the treatment of advanced urothelial cancer (UC) with ...
22
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
... of immune-related organ pathology in patients treated with immune checkpoint ...of immune-related pneumonitis were ...Severe immune-related end-organ damage due to lymphocytic ...
8
Management of pulmonary toxicity associated with immune checkpoint inhibitors
... death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin ’ s lymphoma, bladder, head and neck ...specific immune-related adverse ...of immune-checkpoint inhibitors, ...
10
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
... PD-1/PD-L1 inhibitors are ef- fect persistence ...by immune checkpoint inhibitors (ICPIs) to induce an en- hanced antitumor response ...
21
How we treat neurological toxicity from immune checkpoint inhibitors
... from immune checkpoint inhibitors (ICIs) is incred- ibly ...While immune-related adverse events (irAEs) such as colitis tend to manifest only a few symptoms, or others may be picked up ...
5
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
... Cautious, balanced decision making is required when considering immune checkpoint inhibitors for treatment of patients with pre-exisiting autoimmune conditions or in organ transplant recipients. The ...
8
Cancer immunotherapy beyond immune checkpoint inhibitors
... Indoleamine 2,3-dioxygenase (IDO) is an enzyme that converts tryptophan to kynurenines. These latter pro- mote the formation of Tregs, increase the number of MDSCs, and decrease the activity of CD8 T cells with a ...
25
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
... Immune checkpoint inhibitors (ICIs) have revolutionized the care of several groups of patients with advanced can- cers ...point inhibitors are predominantly approved in late stage patients ...
10
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
... PD-1 is also expressed in T lymphocytes and, similarly to CTLA-4, inhibits T-cell activation by binding PD-L1 and PD-L2 on APCs in the priming phase of the immune response [49]. Notably, PDL-1 and PDL-2 are also ...
27
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
... Neurologic immune-related adverse events reported with ICIs versus those reported in the full database from VigiBase, from Nov 14, 1967, to September 28, ...
9
<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>
... of PD-L1 targeted antibody (durvalumab) consolidation ther- apy or placebo therapy in patients with stage III NSCLC after chemoradiotherapy showed that combination therapy could signi fi cantly improve the median PFS, OS, ...
13
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
... Immune-related adverse event (IRAE) onset may represent one such clinical biomarker for ICI response. Across disease sites, patients who experience IRAEs while on therapy with anti-PD-1 and anti-PD-L1 anti- bodies ...
11
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
... anti-tumor immune response, and a series of preclinical and clinical trials have demon- strated the anti-tumor effect of the CTLA-4 blockade in solid tumors, largely in patients with malignant ...
15